Levofloxacin Use in Pseudomonas Infections
Introduction to Levofloxacin Therapy
- The European Respiratory Society identifies ciprofloxacin as the only fluoroquinolone with reliable oral and IV anti-pseudomonal activity 1
- Levofloxacin has documented activity against Pseudomonas aeruginosa, but it is significantly less potent than ciprofloxacin and should never be used as monotherapy for serious Pseudomonas infections 1, 2
Critical Dosing and Therapy Requirements
- When levofloxacin is used for Pseudomonas coverage, the 750 mg daily dose is mandatory—the standard 500 mg dose lacks adequate anti-pseudomonal activity and will lead to treatment failure 2
- The recommended combination is an anti-pseudomonal β-lactam (piperacillin-tazobactam, ceftazidime, cefepime, or meropenem) PLUS levofloxacin 750 mg IV daily 1, 2
- Combination therapy with an anti-pseudomonal β-lactam is required in all nosocomial or ventilator-associated pneumonia cases 1, 3
- Combination therapy with an anti-pseudomonal β-lactam is required in ICU patients or those with septic shock 1, 2
- Combination therapy with an anti-pseudomonal β-lactam is required in severe community-acquired pneumonia with Pseudomonas risk factors 3
- Combination therapy with an anti-pseudomonal β-lactam is required in structural lung disease (bronchiectasis, cystic fibrosis) 1
- Combination therapy with an anti-pseudomonal β-lactam is required in prior IV antibiotic use within 90 days 1